Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,021 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secondary CV Prevention in South America in a Community Setting: The PURE Study.
Avezum A, Oliveira GBF, Lanas F, Lopez-Jaramillo P, Diaz R, Miranda JJ, Seron P, Camacho-Lopez PA, Orlandini A, Bernabe-Ortiz A, Cordeiro Mattos A, Islam S, Rangarajan S, Teo K, Yusuf S. Avezum A, et al. Among authors: yusuf s. Glob Heart. 2017 Dec;12(4):305-313. doi: 10.1016/j.gheart.2016.06.001. Epub 2016 Oct 20. Glob Heart. 2017. PMID: 27773540 Free article.
Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease.
Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S; Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators. Anand SS, et al. Among authors: yusuf s. Circulation. 2003 Jul 29;108(4):420-5. doi: 10.1161/01.CIR.0000080884.27358.49. Epub 2003 Jul 14. Circulation. 2003. PMID: 12860914
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H; ONTARGET/TRANSCEND Investigators. Teo K, et al. Among authors: yusuf s. Am Heart J. 2004 Jul;148(1):52-61. doi: 10.1016/j.ahj.2004.03.020. Am Heart J. 2004. PMID: 15215792 Clinical Trial.
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction.
Yusuf S, Mehta SR, Díaz R, Paolasso E, Pais P, Xavier D, Xie C, Ahmed RJ, Khazmi K, Zhu J, Liu L; CREATE-ECLA investigators and steering committee. Yusuf S, et al. Am Heart J. 2004 Dec;148(6):1068-78. doi: 10.1016/j.ahj.2004.08.033. Am Heart J. 2004. PMID: 15632895 Free PMC article.
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.
Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L; CREATE-ECLA Trial Group Investigators. Mehta SR, et al. Among authors: yusuf s. JAMA. 2005 Jan 26;293(4):437-46. doi: 10.1001/jama.293.4.437. JAMA. 2005. PMID: 15671428 Clinical Trial.
2,021 results